Zongertinib 71% ORR for HER2-Mutant NSCLC: Key Insights from AACR 2025 AACR 3 Mins Read Introduction Zongertinib (BI 1810631) has shown promising results in treating HER2-mutant non-small cell lung cancer (NSCLC), with a 71% response…
